公开(公告)号：AU2006242431B2

公开(公告)日：2012-11-08

申请号：AU2006242431

申请日：2006-04-28

Applicant: AMGEN INC ,  UCB PHARMA SA

Inventor： SHEN WENYAN ,  LATHAM JOHN ,  PASZTY CHRISTOPHER ,  POPPLEWELL ANDY ,  WINTERS AARON GEORGE ,  ROBINSON MARTYN KIM ,  HOFFMANN KELLY SUE ,  HENRY ALISTAIR JAMES ,  LU HSIENG SEN ,  GRAHAM KEVIN ,  WINKLER DAVID ,  LAWSON ALASTAIR

IPC: C07K14/51 ,  C07K16/18

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

公开(公告)号：AU2006254336B2

公开(公告)日：2012-10-04

申请号：AU2006254336

申请日：2006-05-31

Applicant: UCB PHARMA SA

Inventor： TURET LAURENT ,  ATES ALI ,  QUESNEL YANNICK ,  MERCIER JOEL ,  MICHEL PHILIPPE ,  KENDA BENOIT

IPC: C07D401/06 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/435 ,  C07D403/06 ,  C07D473/00

Abstract: The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：IS2808B

公开(公告)日：2012-09-15

申请号：IS6217

申请日：2002-01-03

Applicant: UCB PHARMA SA

Inventor： ATHWAL DILJEET SINGH ,  BROWN DEREK THOMAS ,  WEIR ANDREW NEIL CHARLES ,  POPPLEWELL ANDREW GEORGE ,  CHAPMAN ANDREW PAUL ,  KING DAVID JOHN

IPC: A61K39/395 ,  C12N15/09 ,  A61K47/48 ,  C12N15/13 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C07K19/00 ,  C12N1/21 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08

公开(公告)号：GB201213503D0

公开(公告)日：2012-09-12

申请号：GB201213503

申请日：2012-07-30

Applicant: UCB PHARMA SA

公开(公告)号：AU2011206584A1

公开(公告)日：2012-07-26

申请号：AU2011206584

申请日：2011-01-13

Applicant: UCB PHARMA SA

Inventor： ELLIS MARK ,  HUMPHREYS DAVID PAUL

IPC: C12N15/70 ,  C07K14/245

Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.

公开(公告)号：IL219653D0

公开(公告)日：2012-06-28

申请号：IL21965312

申请日：2012-05-08

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

IPC: C07K20060101

Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：ES2382879T3

公开(公告)日：2012-06-14

申请号：ES06794542

申请日：2006-09-12

Applicant: UCB PHARMA SA

Inventor： NORMAN TIMOTHY ,  DE CANDOLE BENJAMIN ,  ALI MEZHER

IPC: A61K47/48 ,  C08F4/00 ,  C08F8/04 ,  C08F8/30 ,  C08F220/58

Abstract: Un conjugado de anticuerpo - polímero de peine que tiene la fórmula (Ia) o (Ib) : en las que: y es 1, 2 o 3; m es 1, 2, 3, 4, 5, 6, 7, 8, 9 o 10; 1B1 representa un halógeno; B2 representa H o un halógeno; A representa el residuo de un anticuerpo o uno de sus fragmentos; L representa un grupo enlazador; Y representa un grupo espaciador; y X representa un resto de polímero de peine que comprende w equivalentes de una o más moléculas efectoras y z equivalentes de uno o más restos solubilizantes en agua, en la que X comprende los componentes de fórmula (III) y (IV) en cualquier orden: en las que: w es al menos 1; z es 0 o mayor; T no está o es un grupo enlazador; W es una molécula efectora; Z es un resto solubilizante en agua; M es NH u O; y R1 es metilo o H.

公开(公告)号：IL218696D0

公开(公告)日：2012-05-31

申请号：IL21869612

申请日：2012-03-18

Applicant: UCB PHARMA SA

IPC: C07D20060101

Abstract: The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：AU2006242476B2

公开(公告)日：2012-05-31

申请号：AU2006242476

申请日：2006-04-28

Applicant: AMGEN INC ,  UCB PHARMA SA

Inventor： HOFFMANN KELLY SUE ,  HENRY ALISTAIR JAMES ,  WINTERS AARON GEORGE ,  WINKLER DAVID ,  ROBINSON MARTYN KIM ,  LU HSIENG SEN ,  LAWSON ALASTAIR ,  PASZTY CHRISTOPHER ,  LATHAM JOHN

IPC: C07K14/51 ,  A61K38/10 ,  A61K38/17

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

公开(公告)号：AU2010310100A1

公开(公告)日：2012-05-17

申请号：AU2010310100

申请日：2010-10-21

Applicant: UCB PHARMA SA

Inventor： QUESNEL YANNICK ,  TURET LAURENT ,  MERCIER JOEL

IPC: C07D513/04 ,  A61K31/433 ,  A61P25/08

Abstract: The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.